ClinicalTrials.gg
CompletedNCT00376636Updated Oct 30, 2007

Phase IIa Safety and Efficacy Study of SPP635 in Mild to Moderate Hypertension

A Phase 2 interventional study of SPP635 (drug) in Hypertension, sponsored by Speedel Pharma Ltd.. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2007-10-30.

Sponsored by Speedel Pharma Ltd. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 282 studies in Hypertension with a site in Germany — 29 open to participants now, 46 under way, 11 of them phase 3. Hypertension · Germany.

Enrollment
231st of 250
35 · median 200
Started
2006
with 18 others
Phase 2
24 of 282
none open now
Registered
61st of 282
by date

Among the 282 studies in Hypertension with a site in Germany, this one is the 231st largest by enrollment of the 250 interventional ones that give a count, is one of 19 that started in 2006, is one of 24 in phase 2, and was the 61st registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

29 of the 282 studies in Hypertension with a site in Germany are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 282 studies in Hypertension with a site in Germany, or all of them as a file.
02

Study summary

This study is conducted to investigate the effect of the oral renin inhibitor SPP635 on blood pressure in patients with mild to moderate hypertension.

Read the detailed description

Renin-Angiotensin system blockade is a well established target for treatment of high blood pressure. Blocking the system at the initial step, however, is a rather new concept that could only be implemented very recently through the availability of novel, oral, renin inhibitors. This study investigates the safety and efficacy of a novel oral renin inhibitor, SPP635.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male or female patients with mild to moderate hypertension

Exclusion criteria

Exclusion Criteria:

  • female patients of or breast-feeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
35 participants (actual)

Interventions

  • DrugSPP635 (drug)
06

What researchers measure

Primary outcomes

  1. Lowering of systolic office blood pressure

    Time frame: four weeks

  2. Lowering of diastolic office blood pressure

    Time frame: four weeks

Secondary outcomes

  1. Lowering of systolic and diastolic blood pressure (ABPM)

    Time frame: four weeks

07

Study locations

1 site
  • IKP Bobenheim GmbH
    Mannheim, 68167, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006 and a completion of May 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2006
First posted
Sep 15, 2006
Start
Oct 2006
CompletionActual
May 2007
Last update
Oct 30, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00376636
Lead sponsor
Speedel Pharma Ltd.
First posted
Sep 15, 2006
Start date
Oct 2006
Completion
May 2007
Last update
Oct 30, 2007

Study contacts

Sybille Baumann-Noss, MD
principal investigator · IKP Bobenheim GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion